News headlines about DelMar Pharmaceuticals (NASDAQ:DMPI) have been trending somewhat positive on Sunday, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. DelMar Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.1360797174449 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Reviewing Javelin Mortgage Investment (JMI) & DelMar Pharmaceuticals (DMPI) (americanbankingnews.com)
- Financial Survey: DelMar Pharmaceuticals (DMPI) and Javelin Mortgage Investment (JMI) (americanbankingnews.com)
- Volatile Stock in Focus – DelMar Pharmaceuticals, Inc., (NASDAQ: DMPI) – Stock Watch (stocksnewstimes.com)
- What Analysts Have to Say About Delmar Pharmaceuticals Inc (DMPI)? – AppsforPCdaily (appsforpcdaily.com)
- DelMar Pharmaceuticals, Inc. (DMPI) -Observation about Insider Ownership: PDL BioPharma, Inc. (PDLI) – Wallstreet Investorplace (wallstreetinvestorplace.com)
Several brokerages recently weighed in on DMPI. Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Tuesday, August 8th. Maxim Group downgraded shares of DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of DelMar Pharmaceuticals in a research note on Thursday, October 5th.
Shares of DelMar Pharmaceuticals (DMPI) opened at $0.93 on Friday. DelMar Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). sell-side analysts forecast that DelMar Pharmaceuticals will post -0.61 earnings per share for the current fiscal year.
In other news, CEO Saiid Zarrabian acquired 60,900 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were bought at an average cost of $0.82 per share, with a total value of $49,938.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders acquired 108,400 shares of company stock worth $89,713.
COPYRIGHT VIOLATION WARNING: “DelMar Pharmaceuticals (DMPI) Given Daily Media Sentiment Rating of 0.18” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/26/delmar-pharmaceuticals-dmpi-given-daily-media-sentiment-rating-of-0-18.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.